Skip to main content

Table 1 Baseline clinicopathological characteristics

From: Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis

CharacteristicsBefore PSM (n = 611)After PSM (n = 254)
Right-sided group (n = 141)Left-sided group (n = 470)P valueSMDRight-sided group (n = 127)Left-sided group (n = 127)P valueSMD
Mean age (± SD), years57 (± 12)55 (± 11)0.313− 0.09956 (± 12)54 (± 12)0.3810.086
Gender, n (%)  0.5380.065  0.8940.016
 Male92 (65.2)321 (68.3)  84 (66.1)86 (67.7)  
 Female49 (34.8)149 (31.7)  43 (33.9)41 (32.3)  
Primary tumor characteristics
 Chemotherapy prior to CRC resection  0.218   0.364 
  Yes37 (26.4)156 (33.3)  35 (27.8)43 (33.9)  
  No103 (73.6)313 (66.7)  91 (72.2)84 (66.1)  
 Surgery of CRC and CRLM, n (%)  0.067   0.900 
  Staged69 (48.9)271 (57.7)  62 (48.8)64 (50.4)  
  Combined72 (51.1)199 (42.3)  65 (51.2)63 (49.6)  
 Tumor size, mean (± SD), cm4.2 (± 2.3)3.6 (± 2.2)0.011* 4.2 (± 2.3)3.7 (± 2.4)0.048* 
 T stage, n (%)  0.524   0.841 
  T1/T29 (6.4)40 (8.5)  8 (6.3)10 (7.9)  
  T3/T4118 (83.7)393 (83.6)  114 (89.8)112 (88.9)  
  unknown14 (9.9)37 (7.9)  5 (3.9)5 (3.9)  
 N stage, n (%)  0.546− 0.061  0.363-0.058
  N052 (39.7)188 (40.0)  51 (40.2)43 (33.9)  
  N1/N279 (60.3)249 (53.0)  76 (59.8)84 (66.1)  
  Unknown0 (0)33 (7.0)      
 TNM stage, n (%)  0.441   0.348 
  I2 (1.4)10 (2.1)  2 (1.6)0 (0.0)  
  II7 (5.0)43 (9.1)  7 (5.5)9 (7.1)  
  III21 (14.9)73 (15.5)  21 (16.5)20 (15.7)  
  IV106 (75.2)331 (70.4)  96 (75.6)98 (77.2)  
  Unknown5 (3.5)13 (2.8)  1 (0.7)0 (0.0)  
 Postoperative chemotherapy, n (%)  0.256   0.475 
Yes103 (73.0)366 (77.9)  91 (71.7)97 (76.4)  
No38 (27.0)104 (22.1)  36 (28.3)30 (23.6)  
CRLM characteristics
 Presentation of CRLM, n (%)  0.253− 0.113  0.883− 0.062
  Metachronous35 (24.8)140 (29.8)  31 (24.4)29 (22.8)  
  Synchronous106 (75.2)330 (70.2)  96 (75.6)98 (77.2)  
 Preoperative chemotherapy, n (%)  0.008*0.268  0.900− 0.045
  Yes68 (48.2)287 (61.1)  64 (50.4)62 (48.8)  
  No73 (51.8)183 (38.9)  63 (49.6)65 (51.2)  
 Preoperative CEA (μg/L), (> 200/≤ 200) [n (%)]6/135 (4.3/95.7)23/447 (4.9/95.1)0.755− 0.0086/121 (4.7/95.3)5/122 (3.9/96.1)1.000− 0.042
 Preoperative CA19-9 (kU/L), , (> 35/≤ 35) [n (%)]30/110 (21.4/78.6)97/370 (20.8/79.2)0.867 26/100 (20.6/79.4)24/103 (18.9/81.1)0.754 
 Tumor size (cm), median (IQR)3.0 (2.0–4.5)2.8 (1.6–4.0)0.095− 0.1643.0 (1.8–4.0)3.0 (1.5–4.0)0.944− 0.013
 Position, n (%)  1.000   0.196 
  Unilobar79 (56.4)263 (56.6)  72 (57.1)81 (65.3)  
  Bilobar61 (43.6)202 (43.4)  54 (42.9)43 (34.7)  
 Number of tumors, n (%)  0.6270.082  0.528− 0.015
  Multiple79 (56.0)275 (58.5)  73 (57.5)67 (52.8)  
  Single62 (44.0)195 (41.5)  54 (42.5)60 (47.2)  
 R0 resection, n (%)  1.000   0.886 
  Yes119 (84.4)396 (84.4)  106 (83.5)106 (84.1)  
  No22 (15.6)73 (15.6)  21 (16.5)20 (15.9)  
 Postoperative chemotherapy, n (%)  0.455   1.000 
  Yes98 (69.5)342 (72.8)  89 (70.1)90 (70.9)  
  No43 (30.5)128 (27.2)  38 (29.9)37 (29.1)  
 CRS score, n (%)  0.538   0.922 
  1–290 (64.7)312 (67.7)  88 (71.0)88 (70.4)  
  3–549 (35.3)149 (32.3)  36 (29.0)37 (29.6)  
  1. PSM propensity score matching, SD standard deviation, IQR inter-quartile range, T stage tumor stage, N stage node stage, CRLM colorectal liver metastases, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, R0 resection hepatectomy on patients with clear histological margins, SMD standardized mean differences
  2. *P < 0.05